The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + TACE and placebos (PBO) + TACE: EMERALD-1 subgroup analysis.
 
Jeong Heo
Consulting or Advisory Role - AstraZeneca/MedImmune
Speakers' Bureau - AstraZeneca/MedImmune; Roche
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Kyowa Kirin International; Myriad Genetics; Nihon Servier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience; Eisai (Inst); Incyte; Syneos Health/Immunocore (Inst); Sysmex (Inst)
 
Jung-Hwan Yoon
Research Funding - AstraZeneca; Dicerna; GlaxoSmithKline; Medivir; MSD; NewG Lab Pharma; Pharmicell; Roche; VIR Biotechnology
 
Bruno Sangro
Consulting or Advisory Role - AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb; Eisai; Incyte; Roche/Genentech; Sanofi Pasteur; Sirtex Medical
Speakers' Bureau - AstraZeneca; Eisai; Incyte; Roche
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Eisai; Roche; Sirtex Medical
 
Stephen Chan
Honoraria - AstraZeneca; Eisai; MSD; Roche
Consulting or Advisory Role - AstraZeneca; BMS; Eisai; MSD Oncology; Roche
Research Funding - Eisai; MSD
Travel, Accommodations, Expenses - Ipsen; Roche
 
Joseph Erinjeri
Consulting or Advisory Role - AstraZeneca
 
Marco Matos
No Relationships to Disclose
 
Thomas Decaens
Honoraria - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Gilead Sciences; Ipsen; Roche/Genentech
Research Funding - Enyo Pharma (Inst); Genoscience Pharma (Inst); Guerbet (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Eric Chen
Honoraria - AstraZeneca Canada; Eisai; GlaxoSmithKline; Merck; Pfizer; Roche; Takeda
Research Funding - 1Globe Health Institute; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Repare Therapeutics; Roche Canada
 
Muhammad Beg
No Relationships to Disclose
 
Ana Matilla
Consulting or Advisory Role - AstraZeneca Spain; Roche; Sirtex Medical
Speakers' Bureau - Boston Scientific; Gilead Sciences; Roche
 
Le Thi Tuyet Phuong
No Relationships to Disclose
 
Rebecca Griffin
Employment - AstraZeneca
 
Stephanie Udoye
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Sandra Indiviglio
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai; Roche
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); Eisai (Inst); GE Healthcare (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)